uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
14.25
-0.25 (-1.72%)
At close: Jul 22, 2025, 4:00 PM
14.66
+0.41 (2.88%)
After-hours: Jul 22, 2025, 7:54 PM EDT

Company Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.

The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.

Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.

The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease.

It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering.

uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.
uniQure logo
CountryNetherlands
Founded1998
IPO DateJun 20, 2007
IndustryBiotechnology
SectorHealthcare
Employees209
CEOMatthew Kapusta

Contact Details

Address:
Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
Phone31 20 240 6000
Websiteuniqure.com

Stock Details

Ticker SymbolQURE
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001590560
CUSIP NumberN90064101
ISIN NumberNL0010696654
SIC Code2834

Key Executives

NamePosition
Matthew Craig Kapusta CPAChief Executive Officer and Executive Director
Christian KlemtChief Financial Officer, Principal Financial Officer and GM of Amsterdam Site
Dr. Jeannette Potts J.D., Ph.D.Chief Legal and Compliance Officer and Corporate Secretary
Dr. Walid Abi-Saab M.D.Chief Medical Officer
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Amin Abujoub Ph.D.Chief Technical Operations Officer
Richard Porter Ph.D.Chief Business and Scientific Officer
Dr. Tamara Tugal Ph.D., MBABusiness Development Director
Erin BoyerChief People and Culture Officer
Kylie O'KeefeChief Customer and Strategy Officer

Latest SEC Filings

DateTypeTitle
Jun 30, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 13, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 9, 202510-QQuarterly Report
May 9, 20258-KCurrent Report
Apr 28, 2025ARSFiling
Apr 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025DEF 14AOther definitive proxy statements